Advertisement
Screener

Indaptus Therapeutics, Inc. (INDP) Graph

INDP Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $363.13K; Operating expenses $1.81M; Income tax (m); Net income -$1.79M.
  • 2026-03-31: Research and development $491.13K; Operating expenses $2.16M; Income tax (m); Net income -$2.54M.
  • 2025-12-31: Research and development $2.85M*; Operating expenses $8.16M*; Income tax (m); Net income (m).
  • 2025-09-30: Research and development $1.52M; Operating expenses $2.65M; Income tax (m); Net income -$2.98M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$363.13K$1.81M(m)-$1.79M
2026-03-31$491.13K$2.16M(m)-$2.54M
2025-12-31$2.85M*$8.16M*(m)(m)
2025-09-30$1.52M$2.65M(m)-$2.98M
2025-06-30$2.17M$4.46M(m)-$5.23M
2025-03-31$2.81M$4.57M(m)-$4.53M
2024-09-30$1.47M$3.14M(m)-$3.07M
2024-06-30$1.71M$4.11M(m)-$4.02M
2024-03-31$1.59M$3.94M(m)-$3.81M
2023-09-30$2.23M$4.25M(m)-$3.92M
2023-06-30$1.48M$3.50M(m)-$3.25M
2023-03-31$1.88M$4.46M(m)-$4.25M
2022-09-30$1.61M$3.55M(m)-$3.47M
2022-06-30$1.51M$3.87M(m)-$3.84M
2022-03-31$1.30M$3.40M(m)-$3.37M
2021-09-30$697.67K$3.37M(m)-$3.37M
2021-06-30$391.12K$528.64K$13.00K-$515.48K
2021-03-31$489.72K$613.98K(m)-$612.42K
2020-09-30$1.35M$1.55M(m)-$1.54M
2020-06-30$1.27M(m)$46.00K-$712.62K
2020-03-31(m)(m)(m)-$558.58K

Revenue and expense 6 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$854.26K$3.97M(m)-$4.34M
2025-06-30$4.98M$9.03M(m)-$9.76M
2024-06-30$3.31M$8.05M(m)-$7.82M
2023-06-30$3.36M$7.95M(m)-$7.50M
2022-06-30$2.80M$7.27M(m)-$7.20M
2021-06-30$880.84K$1.14M$33.00K-$1.13M
2020-06-30$3.30M(m)$107.00K-$6.82M

Revenue and expense 9 month

Period endResearch and developmentOperating expensesNet income
2025-09-30$6.50M$11.68M-$12.74M
2024-09-30$4.77M$11.19M-$10.89M
2023-09-30$5.59M$12.20M-$11.42M
2022-09-30$4.41M$10.82M-$10.67M
2021-09-30$1.58M$4.51M-$4.50M
2020-09-30$2.30M$2.83M-$2.81M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-12-31$9.34M$19.83M$1.72K-$20.85M
2024-12-31$7.25M$15.37M$1.70K-$15.02M
2023-12-31$7.62M$16.38M$2.45K-$15.42M
2022-12-31$6.32M$14.91M$30.00-$14.32M
2021-12-31$2.52M$7.73M$1.65K-$7.71M
2020-12-31$2.66M$3.60M$800.00-$3.58M

Similar stocks

Stock NameCountryMarket CapPE Ratio
CRESCENT BIOPHARMA, INC. (CBIO)United States$0.529B-5.20
Evolus, Inc. (EOLS)United States$0.519B-13.32
ARVINAS, INC. (ARVN)United States$0.510B58.38
PUMA BIOTECHNOLOGY, INC. (PBYI)United States$0.507B15.53
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76
CAPRICOR THERAPEUTICS, INC. (CAPR)United States$0.499B-10.81
Ovid Therapeutics Inc. (OVID)United States$0.487B-14.41
ASSEMBLY BIOSCIENCES, INC. (ASMB)United States$0.481B-13,053.96
Altimmune, Inc. (ALT)United States$0.593B-6.43
Monopar Therapeutics (MNPR)United States$0.598B-34.82